SGLT-2 inhibitors (Gliflozins), which are effective in the treatment of type 2 diabetes, have recently been associated with clinical benefits in patients with HFrEF and HFpEF, and have been incorporated in the GDMTs (HFrEF, 1a recommendation; HFpEF, 2a recommendation) [93]. Here, SLC5A2 is linked to type 2 diabetes mellitus.